Biotech Values

[pcrutch]

Are you claiming that they shouldnt test further in high GPNMB patients in this setting or at all? I still want to see more mature data in the current trial before rushing to judgement.

If the latter, I'd say its presumptuous to kill it in the high GPNMB group without looking at the drug in a bit healthier group of patients.

Salvage setting also makes it hard to see the true potential of CDX-011.